# Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

> **NCT06085976** · PHASE2 · UNKNOWN · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 62 (estimated)

## Conditions studied

- Hepatic Carcinoma
- Hepatic Metastasis

## Interventions

- **DRUG:** Octreotide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06085976
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-14
- **Primary completion:** 2025-08-14
- **Final completion:** 2025-11-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06085976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06085976, "Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06085976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*